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Abstract
Objective—To test the feasibility of offering rapid, point-of-care human immunodeficiency virus 
(HIV) testing at community pharmacies and retail clinics.
Design—Pilot program to determine how to implement confidential HIV testing services in 
community pharmacies and retail clinics.
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Setting—21 community pharmacies and retail clinics serving urban and rural patients in the 
United States, from August 2011 to July 2013.
Participants—106 community pharmacy and retail clinic staff members.
Intervention—A model was developed to implement confidential HIV counseling and testing 
services using community pharmacy and retail clinic staff as certified testing providers, or through 
collaborations with organizations that provide HIV testing. Training materials were developed and 
sites selected that serve patients from urban and rural areas to pilot test the model. Each site 
established a relationship with its local health department for HIV testing policies, developed 
referral lists for confirmatory HIV testing/care, secured a CLIA Certificate of Waiver, and 
advertised the service. Staff were trained to perform a rapid point-of-care HIV test on oral fluid, 
and provide patients with confidential test results and information on HIV. Patients with a 
preliminary positive result were referred to a physician or health department for confirmatory 
testing and, if needed, HIV clinical care.
Main outcome measures—Number of HIV tests completed and amount of time required to 
conduct testing.
Results—The 21 participating sites administered 1,540 HIV tests, with 1,087 conducted onsite 
by staff during regular working hours and 453 conducted at 37 different HIV testing events (e.g., 
local health fairs). The median amount of time required for pretest counseling/consent, waiting for 
test results, and posttest counseling was 4, 23, and 3 minutes, respectively. A majority of the sites 
(17) said they planned to continue HIV testing after the project period ended and would seek 
assistance or support from the local health department, a community-based organization, or an 
AIDS service organization.
Conclusion—This pilot project established HIV testing in several community pharmacies and 
retail clinics to be a feasible model for offering rapid, point-of-care HIV testing. It also 
demonstrated the willingness and ability of staff at community pharmacies and retail clinics to 
provide confidential HIV testing to patients. Expanding this model to additional sites and 
evaluating its feasibility and effectiveness may serve unmet needs in urban and rural settings.
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By the end of 2010, approximately 1.1 million people living in the United States were 
infected with human immunodeficiency virus (HIV), with approximately 18% of these 
individuals unaware of their health status.1–4 In recent years, approximately 50,000 new 
HIV diagnoses have been reported annually.3 To access testing services for HIV, patients 
must typically visit a health department-supported clinical care site (e.g., sexually 
transmitted disease [STD] clinic, community health center, or emergency department), 
physician’s office, or HIV testing site.
Unfortunately, for patients in such areas as the rural Southeast, access to these services may 
be hindered by both distance and stigma.5 However, 70% of rural consumers live within 15 
miles of a pharmacy, and nearly 90% of urban consumers are just 2 miles away from their 
local pharmacy.6 Additionally, as of 2009, approximately 30% of the U.S. population lived 
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within a 10-minute drive of a retail clinic (typically located within a pharmacy, supermarket, 
or other retail store).6,7
Going to a pharmacy or retail clinic is considered a socially innocuous act, unlike visiting an 
HIV testing site. Thus, implementing HIV testing in such settings could potentially 
overcome the obstacles associated with conventional testing centers.8 Pharmacies and retail 
clinics offer a vast, largely untapped potential for the delivery of HIV testing in settings that 
are more accessible and, for some people, less stigmatizing than traditional testing sites.9,10
Published examples of pharmacy-provided HIV testing reveal that some of the sites used 
third-party partners to conduct the testing,11,12 while others relied on pharmacy staff.13 
Pharmacies have been used as HIV testing sites during HIV testing campaigns, such as 
National HIV Testing Day and, in some cases, as standing sites for third-party HIV testing 
partners to conduct HIV tests.14,15
We report on a pilot program to determine how to implement confidential HIV testing 
services in community pharmacies and retail clinics using pharmacy and retail clinic staff as 
certified testing providers or collaborating with organizations that could provide HIV testing 
at these sites.
Objective
The objective of this project was to test the feasibility of offering rapid, point-of-care HIV 
testing at community pharmacies and retail clinics.
Methods
In August 2011, the U.S Centers for Disease Control and Prevention (CDC) awarded a 2-
year contract to ASHLIN Management Group, Inc., to develop and implement an HIV 
testing model that could be adopted by a variety of pharmacies (e.g., chain and independent 
pharmacies) and retail clinics. An expert panel was formed to provide guidance on 
development of training for the model and to assist with the identification of sites in the 
United States that would be willing to sign subcontracts to participate in the project.
Participating sites were required to have or obtain a Clinical Laboratory Improvements 
Amendments of 1988 (CLIA) Certificate of Waiver, which would allow them to perform 
laboratory tests that are categorized as “simple laboratory examinations and procedures that 
have an insignificant risk of an erroneous result.”16 We also developed a curriculum and 
training module with strategies, materials, and procedures designed to support pharmacists, 
nurses, and nurse practitioners in the administration of rapid, point-of-care HIV testing at 
community pharmacies or retail clinics (Table 1). The training sessions, which were 
delivered either in person or by webinar, provided recommendations and requirements for 
obtaining patient permission and consent, as well as instructions for staff on how to deliver 
rapid HIV test results in an accurate, sensitive, and culturally appropriate manner.
Each site engaged its local health department for assistance with local norms for HIV point-
of-care testing and for help developing a list of sites for confirmatory HIV testing and HIV 
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care services. In one jurisdiction, patients with reactive test results were referred to a patient 
navigator to facilitate the linkage to confirmatory testing and care. Each site also developed 
a list of referrals for other issues that might arise during counseling on HIV test results (e.g., 
evaluation for sexually transmitted infections [STIs]).
Site staff were taught about the variety of point-of-care HIV tests available at the time of the 
study. We used the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test (OraSure 
Technologies, Inc., Bethlehem, PA), the choice of which was made from the available 
CLIA-waived, rapid, point-of-care HIV tests available in 2011 and is not intended to imply 
CDC’s endorsement over other products. Staff were trained in how to administer the test on 
oral fluid by medical professionals hired for this project or by service representatives from 
the product manufacturer.
Staff were also instructed to provide basic information on HIV risk reduction to those 
patients with nonreactive HIV test results. Patients with reactive test results (preliminary 
positive) were informed about the meaning of the test and the need for a confirmatory test, 
as well as provided a referral for confirmatory testing tailored to local requirements.
We implemented the project in two phases. During Phase 1, seven sites were selected in 
early 2012 for project participation, six of which received training between March and July 
2012. (One of the initial seven sites withdrew before training due to the inability to obtain a 
CLIA Certificate of Waiver.) After the Phase 1 sites were trained, we refined the training 
modules and processes. In Phase 2, we selected and trained 16 additional sites from October 
2012 through May 2013, with one site withdrawing after training but before any tests were 
conducted.
The testing service was advertised in a variety of ways, including in-store promotional flyers 
and pamphlets, local newspaper articles, flyers in customer bags, websites, and social media. 
For each test, the staff completed a log of the start and stop time of 1) pretest counseling, 2) 
incubation while waiting for test results (when staff was either not otherwise engaged, was 
conducting other work in the pharmacy, or seeing another patient in the retail clinic), and 3) 
posttest counseling. The analysis that follows includes data from the 21 sites that conducted 
at least one rapid, point-of-care HIV test.
Results
From August 2011 through July 2013, we trained 106 staff at 21 sites (18 community 
pharmacies, one retail clinic, one nurse-run HIV testing service at an Indian Health Service 
Clinic, and one multisite venue where faculty from a school of pharmacy partnered with 
multiple community pharmacies) to conduct HIV tests. Pharmacists at one of these sites had 
already implemented HIV testing as part of another pilot project,13 while pharmacists at a 
second site had already implemented both HIV and hepatitis C testing in partnership with 
the local health department.17 Nineteen of the participating sites used in-store pharmacists or 
retail clinic staff to conduct the testing; one site partnered with the local health department to 
do testing every other weekend at the store; and the multisite program relied on pharmacy 
school faculty to conduct testing.
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The six Phase 1 sites began initial testing between May and July 2012. Five of these sites 
continued to provide testing through July 2013, while the site that partnered with the local 
health department withdrew from the project after 11 months of participation due to 
challenges with maintaining staff to support the service. The 15 Phase 2 sites began testing 
between December 2012 and May 2013, with 14 continuing to provide testing through July 
2013 and one withdrawing after 5 months due to the store closing.
The 21 participating sites conducted 1,540 HIV tests (median: 93; interquartile range [IQR]: 
67–129; range: 1–370), with 939 tests completed by the initial six Phase 1 sites and 601 by 
the 15 Phase 2 sites (Figure 1). On a per-month basis, 11 of the sites conducted 1–5 tests, 5 
of the sites conducted 6–10 tests, 4 sites conducted 11–25 tests, and the multisite venue 
operated by pharmacy school faculty conducted more than 25 tests. The spike in testing in 
June and July of each year likely corresponds with increased efforts around National HIV 
Testing Day (June 27).
Nine of the sites participated in 37 HIV testing events (e.g., local health fairs, one-time 
events in a pharmacy), during which 453 tests were conducted. The remaining 1,087 tests 
were conducted onsite by community pharmacy and retail clinic staff members during 
regular working hours. There were 1,508 nonreactive test results, 24 (1.6%) reactive test 
results (preliminary positives), and 8 invalid tests.
A majority of the sites (17) said they planned to continue HIV testing after the project period 
ended and would seek assistance or support from the local health department, a community-
based organization, or an AIDS service organization.
Preliminary positive test results
The 24 reactive test results were identified at 10 of the project sites (range: 1–8 per site). In 
each instance, the pharmacist or nurse practitioner counseled the patient and provided a 
referral for confirmatory testing. In 16 of these cases, the outcome of confirmatory testing 
was unknown to site staff. Of the remaining eight reactive test results, five were determined 
to be false-positive on confirmatory testing, two involved persons previously diagnosed with 
HIV, and one was confirmed as a new HIV case.
Staff–patient interaction time
The time required to conduct the rapid point-of-care HIV test was categorized into three 
components: 1) pretest time, which involved initial patient counseling, obtaining informed 
consent, and collecting the specimen; 2) time waiting for the test result, during which staff 
engaged in nontesting-related work; and 3) posttest time, which involved sharing the test 
result with the patient and providing risk-reduction information for nonreactive test results 
or making arrangements to obtain a confirmatory test for reactive test results.
Pretest counseling/consent took a median of 4 minutes (IQR: 2–7 minutes), while posttest 
counseling took a median of 3 minutes (IQR: 2–5 minutes). Posttest counseling took 
considerably longer for reactive tests compared with nonreactive tests (Figure 2). The time 
spent waiting for test results (staff nonengaged time) was a median of 23 minutes (IQR: 20–
30 minutes). The amount of nonengaged time observed in this study included the 20-minute 
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processing time required for the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test and 
would likely vary with use of other rapid, point-of-care HIV test kits.
Discussion
The results of our pilot study suggest that confidential HIV testing services can be 
administered by existing staff at community pharmacies and retail clinics and can be 
successfully integrated into a busy work environment with a modest amount of staff–patient 
interaction time. These novel venues for confidential HIV testing services can supplement 
conventional HIV testing sites such as health departments, doctors’ offices, and community-
based organizations. Additionally, the pharmacists, nurses, and nurse practitioners working 
at community pharmacies and retail clinics can host or participate in event-based HIV 
testing activities, extending the model’s reach in a manner not originally anticipated.
Although one participating site was able to successfully partner with its local health 
department as a third-party provider of onsite testing for a period of time, the site was 
ultimately unable to continue with this approach as a result of staff and budget constraints. 
Partnership approaches bring resources to a pharmacy or retail clinic to help conduct HIV 
testing, but sustainability of the partnership may not be within the pharmacy’s control. 
Nevertheless, sites that lack the staff to conduct such testing may wish to consider a third-
party testing model.
Pharmacies and retail clinics are convenient places to disseminate health information to a 
broad array of patients seeking medical advice and information who otherwise may have 
limited access to health care providers.18–20 They may also be points of contact where there 
are opportunities to reach populations at risk for other STIs or infectious diseases. Therefore, 
expansion of the testing model studied here to include other point-of-care, CLIA-waived 
screening tests (e.g., hepatitis C) should be feasible in these types of sites.21
The training provided to study participants focused on educating pharmacy and retail clinic 
staff about HIV infection and HIV testing, providing results to patients, and having a system 
for referral for confirmatory HIV testing and linkage to care. Pharmacists, nurses, and nurse 
practitioners are already skilled in patient counseling and adhere to confidentiality standards 
at their practice sites; the training offered in this program simply augmented these skills 
around confidentiality requirements unique to HIV testing and delivery of HIV test results, 
which has been identified as a need.8,22
The test kit for this project was chosen from among the available options at the time the 
project started in 2011. By 2014, there were five CLIA-waived, rapid, point-of-care HIV test 
kits commercially available (with more in the pipeline) from which a pharmacy or retail 
clinic could choose, as well as a rapid HIV self-test sold for in-home use that could also be 
administered at a pharmacy or retail clinic.23–25 HIV testing recommendations, local health 
department preferences for testing, test kit-specific requirements and performance 
characteristics, and cost should all be considered when deciding which test to use. 
Additionally, involving the local health department prior to offering confidential HIV testing 
Weidle et al. Page 6
J Am Pharm Assoc (2003). Author manuscript; available in PMC 2016 January 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
services is essential to ensuring that procedures for counseling and referral are consistent 
with local norms or requirements.
An essential component of this project was making arrangements for persons with 
preliminary positive test results to obtain confirmatory testing; however, we found that 
pharmacy and retail clinic staff were not always aware of patients’ final testing status, 
despite reasonable attempts at contacting them. Once a referral is made for confirmatory 
testing, the responsibility for patient management is turned over to the respective clinician 
or, in some cases, a patient navigator. Although patients with reactive test results are not 
obligated to return to the initial testing site, future HIV testing programs in these settings 
should emphasize methods to assist pharmacists or retail clinic staff in documenting that 
such patients have followed up with the referred clinician or patient navigator.
Pharmacies and retail clinics could be convenient settings for testing patients at high risk of 
acquiring HIV for whom repeat (every 3–6 months) HIV testing is recommended. The 
window of time in which an HIV infection may be detected varies by test, so high-risk 
persons with repeated potential exposures to HIV may require testing with diagnostic 
approaches that minimize this window.23,26
Other innovative approaches to the implementation of rapid, point-of-care HIV testing at 
community pharmacies or retail clinics, which would require further development and 
evaluation, include use in monitoring persons taking antiretroviral therapy as preexposure 
prophylaxis against acquisition of HIV or use as a screening test before initiating 
nonoccupational, post-exposure prophylaxis as part of a collaborative practice model 
agreement with a primary care provider.
Limitations
The pharmacy and retail clinic partners who agreed to participate in this pilot project may 
represent early adopters of an innovative service. The model may not be as readily 
implemented in pharmacies and retail clinics with staffing constraints, inadequate physical 
infrastructure (e.g., no private testing area), or lack of staff interest. Some sites that were 
approached to participate in the project declined, but we did not capture their reasons for 
declining in a systematic fashion.
The number of HIV tests conducted by different pharmacies and retail clinics reflected 
multiple enabling and hindering factors at each site and should not be considered 
representative of the maximal capacity to conduct screenings. For example, advertising was 
noted as a challenge by many sites; while some said advertising was successful in attracting 
clients to the program, others said it failed to bring in many clients. Many sites also 
expressed challenges in addressing perceived stigma associated with HIV. We were not able 
to systematically assess these factors within the scope of this project.
The rate of reactive test results should not be interpreted as reflective of what might be 
attained if the model is more widely disseminated. For example, while pharmacies and retail 
clinics in high-prevalence areas may identify more HIV-infected patients, testing sites in 
some rural areas with low HIV prevalence may have fewer patients with reactive test results 
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yet still serve an important role by providing the service in an area of unmet need for HIV 
testing.
Pharmacy and retail clinic partners were subcontracted for their participation in this project, 
and test kits and controls were provided through the project at no cost; the implications of 
implementing HIV testing services without this support warrant further investigation.
Conclusion
The success of the pilot program reported here demonstrates the feasibility of implementing 
confidential HIV testing services in community pharmacies and retail clinics at several sites 
in the United States using pharmacy and retail clinic staff as certified testing providers or 
collaborating with organizations that could provide HIV testing at these sites. Involvement 
and support of local health departments was a key feature of this project and can foster 
meaningful integration with public health promotion activities related to HIV testing at 
community pharmacies and retail clinics.27,28 Expansion and further evaluation of this 
model will require securing the support of management of individual sites and training 
additional pharmacists, nurses, and nurse practitioners interested in offering the service and 
collecting and analyzing outcome data.
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At a Glance
Synopsis
This pilot project developed and tested a model for implementing confidential human 
immunodeficiency virus (HIV) counseling and testing services at 21 community 
pharmacies and retail clinics in the United States. Between August 2011 and July 2013, 
106 staff members were trained and conducted 1,540 rapid, point-of-care HIV tests, 
yielding 1,508 nonreactive results, 24 reactive results (of which only one was confirmed 
as a new HIV case), and 8 invalid tests. Pretest counseling/consent took a median of 4 
minutes, while posttest counseling took a median of 3 minutes. Wait time for test results 
was a median of 23 minutes, approximately 20 minutes of which included processing 
time specific to the test kit selected for the pilot project.
Analysis
Access to HIV testing services typically requires that patients visit a health department, 
physician, or HIV testing site, which in some jurisdictions can require traveling long 
distances. Pharmacies and retail clinics offer a vast, largely untapped potential for the 
delivery of HIV testing in settings that are more accessible and, for some people, less 
stigmatizing than traditional testing sites. The results of this pilot project suggest that 
confidential HIV testing services can be administered by existing staff at community 
pharmacies and retail clinics and successfully integrated into a busy work environment 
with a modest amount of staff– patient interaction time. The success of this model also 
suggests that community pharmacies and retail clinics may potentially serve as future 
points of contact for reaching populations at risk for other sexually transmitted infections 
(STIs) or infectious diseases.
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Figure 1. 
Number of HIV tests completed by community pharmacies and retail clinics per month, 
May 2012 – July 2013
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Figure 2. 
Mean time to conduct an HIV test in community pharmacies and retail clinics
Weidle et al. Page 12
J Am Pharm Assoc (2003). Author manuscript; available in PMC 2016 January 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Weidle et al. Page 13
Table 1
Primary training objectives for performing HIV testing in community pharmacies and retail clinics
Objectives
Understand the current status of the HIV epidemic in the United States and local communities.
Summarize the major reasons why routine HIV testing is important.
Understand the CDC recommendations for routine testing and describe appropriate HIV testing methods.
Identify ways to reach out and support the community for HIV testing.
Determine recommendations and requirements for permission, consent, and pre- and posttest counseling in the state in which rapid HIV testing 
is performed.
Establish competence in performing, reading, and interpreting a rapid HIV test:
■ Understand the basic process of how a rapid, point-of-care HIV test works.
■ Identify and list all materials required to perform a rapid HIV test, and identify and set up a testing site.
■ Establish competence in performing a rapid HIV test.
■ Accurately read and interpret a rapid HIV test result.
■ Establish site quality control procedures to ensure sustained accuracy of testing with a rapid HIV test.
Provide accurate, sensitive, and culturally appropriate information regarding rapid HIV test results.
Identify sites for linkage to clinical care and confirmatory testing.
Identify and address possible barriers to HIV testing in the setting and/or locale.
Abbreviations used: HIV, human immunodeficiency virus; CDC, Centers for Disease Control and Prevention.
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